Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective

Clinical Pharmacokinetics

Volumn 36, Issue 4, 1999, Pages 265-276

  Martin, Ulrich ^a,b   Kaufmann, Burchard ^a   Neugebauer, Günter ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HALF LIFE TIME; HUMAN; INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I; CORONARY THROMBOSIS; DOGS; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; RABBITS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032906274     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936040-00002     Document Type: Review

References (57)

1. 1. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
2. 2. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993; 87: 1792-805
3. 3. Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21: 1391-5
4. 4. Ohmann EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-91
5. 5. ISFC and WHO Task Force on Myocardial Reperfusion. Reperfusion in acute myocardial infarction. Circulation 1994; 90: 2091-102
6. 6. Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5: 93-100
7. 7. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue type plasminogen activator. J Biol Chem 1982; 257: 2912-9
8. 8. Kohnert U, Horsch B, Fischer S. A variant of tissue plasminogen activator (t-PA) comprised of the kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed Chinese hamster ovary cells. Fibrinolysis 1993; 7: 365-72
9. 9. Martin U, Sponer G, Strein K. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro. Blood Coagul Fibrinolysis 1993; 4: 235-42
10. 10. Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: the lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis Proteolysis 1997; 11: 129-35
11. 11. Martin U, Fischer S, Kohnert U, et al. Thrombolysis with an Escherichica coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 1991; 65: 560-4
12. 12. Martin U, Fischer S, Kohnert U, et al. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. J Cardiovasc Pharmacol 1991; 18: 111-9
13. 13. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22
14. 14. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992; 19: 433-40
15. 15. Martin U, Fischer S, Sponer G. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis. J Am Coll Cardiol 1993; 22: 914-22
16. 16. Marder VJ, Shulman NR. High molecular weight derivatives of human fibrinogen produced by plasmin. J Biol Chem 1969; 244: 2120-4
17. 17. Martin U, Fischer S, Kohnert U, et al. Pharmacokinetic properties of an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. Thromb Res 1991; 62: 137-46
18. 18. Martin U, Kohler J, Sponer G, et al. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 1992; 6: 39-43
19. 19. Rijken DC, Groeneveld E, Barrett-Bergshoeff MM. In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. Thromb Haemost 1994; 72: 906-11
20. 20. Martin U, Sponer G, Strein K. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. Drug Metab Dispos 1993; 21: 236-41
21. 21. Kuiper J, van de Bilt H, Martin U, et al. Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. Thromb Haemost 1995; 74: 1501-10
22. 22. Martin U, Doerge L, Stegmeier KH, et al. Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. Drug Metab Dispos 1996; 24: 288-91
23. 23. Martin U, Sponer G, Koenig R, et al. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1992; 3: 139-47
24. 24. Martin U, Sponer G, Strein K. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis. Int J Hematol 1992; 56: 143-53
25. 25. Martin U, Doerge L, Fischer S. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary artery thrombosis. Br J Pharmacol 1996; 118: 271-6
26. 26. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82
27. 27. Antman EM, TIMI 9B Investigators. Hirudin in acute myocardial infarction. Circulation 1996; 94: 911-21
28. 28. Kientsch-Engel R, Boehm E, Neubert P, et al. No induction of antibodies in patients treated with the recombinant plasminogen activator reteplase (BM 06.022). Fibrinolysis Proteolysis 1997; 11: 259-64
29. 29. Murota T, Miyagawa M, Inoue Y, et al. Antigenicity of GMK-527 (rt-PA). Jpn Pharmacol Ther 1988; 16 (Suppl. 5): 143-53
30. 30. Reed BR, Chen A, Tanswell P, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost 1990; 64: 276-80
31. 31. Cugno M, Cicardi M, Colucci M, et al. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost 1996; 76: 234-8
32. 32. Lynch M, Littler WA, Pentecost BL, et al. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Br Heart J 1991; 66: 139-42
33. 33. Garabedian HD, Gold HK, Leinbach RC, et al. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of the recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 1986; 58: 673-9
34. 34. Tanswell P, Seifried E, Su PCAF, et al. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 1989; 46: 155-62
35. 35. Tebbe U, Tanswell P, Seifried E, et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448-53
36. 36. Verstraete M, van de Werf F, Tranchesi B, et al. Bolus alteplase [letter]. Lancet 1989 Oct 21; 2 (8669): 989-90
37. 37. Seifried E, Tanswell P, Rijken DC, et al. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Drug Res 1988; 38: 418-22
38. 38. Data on file, Boehringer Mannheim GmbH, 1992
39. 39. Martin U, von Moellendorf E, Akpan W, et al. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1991; 50: 429-36
40. 40. Neuhaus KL, von Essen R, Vogt A, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol 1994; 24: 55-60
41. 41. Data on file, Boehringer Mannheim GmbH, 1992
42. 42. Kohnert U, Hellerbrand K, Martin U, et al. The recombinant Escherichia roli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis 1996; 10: 93-102
43. 43. Martin U, Kohnert U, Hellerbrand K, et al. Effective thrombolysis by a recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator in the rabbit model of jugular vein thrombosis. Fibrinolysis 1996; 10: 87-92
44. 44. Martin U, Kohnert U, Stern A, et al. Comparison of the recombinant Escherichia cali-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Thromb Haemost 1996; 76: 1096-101
45. 45. Martin U, von Moellendorf E, Akpan W, et al. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74
46. 46. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19: 885-91
47. 47. Seifried E, Tanswell P, Ellbrueck D, et al. Pharmacokinetics and hemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost 1989; 61: 497-501
48. 48. Tebbe U, von Essen R, Smolarz A, et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993; 72: 518-24
49. 49. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-32
50. 50. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891-8
51. 51. Seifried E, Mueller MM, Martin U, et al. Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects on the hemostatic system. Ann NY Acad Sci 1992; 667: 417-20
52. 52. Gruenewald M, Mueller M, Ellbrueck D, et al. Double-versus single-bolus thrombolysis with reteplase for acute myocardial infarction: a pharmacokinetic and pharmacodynamic study. Fibrinolysis Proteolysis 1997; 11: 137-45
53. 53. INJECT Investigators. Randomised, double-blind comparison of reteplase double bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-36
54. 54. Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5
55. 55. GUSTO Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23
56. 56. Martin U, Sponer G, Strein K. Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022. J Cardiovasc Pharmacol 1993; 21: 455-61
57. 57. Tebbe U, Graf A, Kamke W, et al. Thrombolytic therapy in acute massive pulmonary embolism: double bolus reteplase versus conventional alteplase infusion in a randomized controlled trial [abstract no. 1917]. Eur Heart J 1997; 18 Suppl.: 346